October 18, 2023 06:54 AM EDT
R&D

Takeda's stem cell ther­a­py flunks PhI­II test study­ing the drug in Crohn's dis­ease

Katherine Lewin

News Reporter

Take­da’s al­lo­gene­ic stem cell ther­a­py flunked a Phase III study for the treat­ment of a com­mon com­pli­ca­tion of Crohn’s dis­ease,

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

FDA re­jects Stealth's rare dis­ease drug, but of­fers po­ten­tial for ac­cel­er­at­ed ap­proval

Mer­ck, Dai­ichi Sankyo scrap FDA ap­pli­ca­tion for HER3 ADC af­ter sur­vival miss

DNA gi­ant Il­lu­mi­na spawned an ecosys­tem of com­peti­tors and cus­tomers

Up­dat­ed: Trump ad­min­is­tra­tion halts more than $750M in funds for Mod­er­na’s bird flu vac­cine

In­tel­lia re­ports case of liv­er tox­i­c­i­ty in AT­TR gene edit­ing study

sponsored

From weeks to days: how Aizon In­tel­li­gent Agents trans­form phar­ma val­i­da­tion

A service from the Financial Times